These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17371824)

  • 41. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.
    Delang L; Vliegen I; Leyssen P; Neyts J
    J Hepatol; 2012 Jan; 56(1):41-8. PubMed ID: 21703175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
    Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
    Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Replication studies using genotype 1a subgenomic hepatitis C virus replicons.
    Gu B; Gates AT; Isken O; Behrens SE; Sarisky RT
    J Virol; 2003 May; 77(9):5352-9. PubMed ID: 12692237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background.
    Graham DJ; Stahlhut M; Flores O; Olsen DB; Hazuda DJ; Lafemina RL; Ludmerer SW
    Antiviral Res; 2006 Jan; 69(1):24-30. PubMed ID: 16297457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
    Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.
    Tomei L; Altamura S; Bartholomew L; Bisbocci M; Bailey C; Bosserman M; Cellucci A; Forte E; Incitti I; Orsatti L; Koch U; De Francesco R; Olsen DB; Carroll SS; Migliaccio G
    J Virol; 2004 Jan; 78(2):938-46. PubMed ID: 14694125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.
    Yi G; Deval J; Fan B; Cai H; Soulard C; Ranjith-Kumar CT; Smith DB; Blatt L; Beigelman L; Kao CC
    Antimicrob Agents Chemother; 2012 Feb; 56(2):830-7. PubMed ID: 22143520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
    Brown AN; McSharry JJ; Adams JR; Kulawy R; Barnard RJ; Newhard W; Corbin A; Hazuda DJ; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1170-81. PubMed ID: 22155837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
    Maynard A; Crosby RM; Ellis B; Hamatake R; Hong Z; Johns BA; Kahler KM; Koble C; Leivers A; Leivers MR; Mathis A; Peat AJ; Pouliot JJ; Roberts CD; Samano V; Schmidt RM; Smith GK; Spaltenstein A; Stewart EL; Thommes P; Turner EM; Voitenleitner C; Walker JT; Waitt G; Weatherhead J; Weaver K; Williams S; Wright L; Xiong ZZ; Haigh D; Shotwell JB
    J Med Chem; 2014 Mar; 57(5):1902-13. PubMed ID: 23672667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selection and characterization of drug-resistant HCV replicons in vitro with a flow cytometry-based assay.
    Robotham JM; Nelson HB; Tang H
    Methods Mol Biol; 2009; 510():227-42. PubMed ID: 19009265
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5.
    Legrand-Abravanel F; Henquell C; Le Guillou-Guillemette H; Balan V; Mirand A; Dubois M; Lunel-Fabiani F; Payan C; Izopet J
    Antivir Ther; 2009; 14(5):723-30. PubMed ID: 19704176
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.
    Trozzi C; Bartholomew L; Ceccacci A; Biasiol G; Pacini L; Altamura S; Narjes F; Muraglia E; Paonessa G; Koch U; De Francesco R; Steinkuhler C; Migliaccio G
    J Virol; 2003 Mar; 77(6):3669-79. PubMed ID: 12610142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.
    Robinson M; Tian Y; Delaney WE; Greenstein AE
    Proc Natl Acad Sci U S A; 2011 Jun; 108(25):10290-5. PubMed ID: 21646519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
    Hao W; Herlihy KJ; Zhang NJ; Fuhrman SA; Doan C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2007 Jan; 51(1):95-102. PubMed ID: 17060518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.